United States · Platforms & data · Stocktwits

CADL Stock Tumbles 38% After-Hours As Candel Pushes Prostate Cancer FDA Application Timeline To Mid-2027

Published by Stocktwits · United States 1 d ago

Detailed summary

Candel said it is in continuing dialogue with the FDA regarding the Biologics License Application (BLA) submission for aglatimagene in intermediate- to high-risk localized…

Read the full article on Stocktwits Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)

Also worth reading

MarketBeat

Sensus Healthcare (NASDAQ:SRTS) Share Price Crosses Below 50-Day Moving Average Following Weak Earnings

Seeking Alpha

Sagicor Financial declares $0.075 dividend

Investing.com

Venture Global senior VP Fory Musser sells $6.58M in stock

MarketWatch

FAA lifts rare nationwide ground stop on flights; air travel may take days to recover

CNBC

Lutnick faces questions over Nvidia spy scandal. His sons' firm has deep ties to the chipmaker

Benzinga